Managed Healthcare Executive October 16, 2024
Logan Lutton, Peter Wehrwein, Managing Editor

Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, highlights the expected shift of Medicare beneficiaries towards Medicare Advantage Prescription Drug (MA-PD) plans.

Due to decreasing Prescription Drug Plan (PDP) options, rising PDP premiums and the additional benefits and risk management capabilities offered by MA-PD plans, there is an expected shift toward MA-PD plans, according to Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy, BluePeak Advisors.

“We’re really not going to see how that membership shifts right until we get through...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Conferences / Podcast, Insurance, Medicare Advantage, Trends
Related Articles:
CMS ending VBID model due to high costs
CMS ends value-based Medicare Advantage model: 5 things to know
Trends 2025: Medicare Advantage prospects strong despite challenges
How the Federal Government Could Push People Toward Medicare Advantage – And Replace Traditional Medicare
The pros and cons of Medicare Advantage plans - 2

Share This Article